Dolutegravir as monotherapy in HIV-1-infected individuals with suppressed HIV viraemia

Reducing drug burden is a key challenge for achieving lifelong suppressive HIV therapy. Dolutegravir, with a high potency, long half-life and high genetic barrier, offers potential for monotherapy. This observational single-centre study enrolled all patients with HIV RNA (viral load) 350 cells/mm(3)...

Full description

Saved in:
Bibliographic Details
Published in:Journal of antimicrobial chemotherapy 2016-09, Vol.71 (9), p.2646-2650
Main Authors: Katlama, C, Soulié, C, Caby, F, Denis, A, Blanc, C, Schneider, L, Valantin, M-A, Tubiana, R, Kirstetter, M, Valdenassi, E, Nguyen, Thuy, Peytavin, G, Calvez, V, Marcelin, A-G
Format: Article
Language:English
Subjects:
Adult
Female
Heterocyclic Compounds, 3-Ring - therapeutic use
HIV Infections - drug therapy
HIV Integrase Inhibitors - therapeutic use
HIV-1 - isolation & purification
Human health and pathology
Humans
Infectious diseases
Life Sciences
Maintenance Chemotherapy - methods
Male
Medication
Middle Aged
Pharmaceutical sciences
Sustained Virologic Response
Treatment Outcome
Viral Load
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Reducing drug burden is a key challenge for achieving lifelong suppressive HIV therapy. Dolutegravir, with a high potency, long half-life and high genetic barrier, offers potential for monotherapy. This observational single-centre study enrolled all patients with HIV RNA (viral load) 350 cells/mm(3) and with no failure under integrase inhibitor therapy who had switched from suppressive ART to dolutegravir monotherapy (50 mg/day). Primary outcome was proportion of patients with viral load
ISSN:0305-7453
1460-2091
DOI:10.1093/jac/dkw186